In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?

Executive Summary

The industry's genericization problem will seriously constrain Big Pharma's ability to pay for late-stage development on all its products. One potential solution is being developed by Pfizer, whose top R&D execs see out-partnering as a way to free up resources for key programs and to expand R&D capacity. In this interview with R&D boss Martin Mackay, Mackay reports that Pfizer is building up a war-chest of out-licensing and partnering candidates, pursuing a wide variety of transactions--including project financing, straight out-licensing and spinoffs. But the extent of Pfizer's long-term commitment to out-partnering still isn't clear.
Advertisement

Related Content

Pharma R&D: Doing the Same Thing That Didn't Work Before
Pfizer's Increasingly Specialist Focus
Pfizer Restructures for a More Flexible Future
Pharma's Strategic Divide: Focus or Diversify
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Finding a Way Out of Pharma's Dealmaking Dilemma
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
Best Laid Plans: Pfizer's Torcetrapib Tanks
Canary in the Coalmine: Pfizer R&D
A Recipe for Acquisition: the Esperion Strategy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel